KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Work In Process (2016 - 2021)

Biomarin Pharmaceutical's Work In Process history spans 12 years, with the latest figure at $412.4 million for Q3 2021.

  • For the quarter ending Q3 2021, Work In Process rose 39.01% year-over-year to $412.4 million, compared with a TTM value of $412.4 million through Sep 2021, up 39.01%, and an annual FY2020 reading of $308.3 million, down 11.91% over the prior year.
  • Work In Process for Q3 2021 was $412.4 million at Biomarin Pharmaceutical, up from $374.0 million in the prior quarter.
  • The five-year high for Work In Process was $412.4 million in Q3 2021, with the low at $194.6 million in Q1 2018.
  • Average Work In Process over 5 years is $295.3 million, with a median of $296.7 million recorded in 2020.
  • Year-over-year, Work In Process skyrocketed 51.46% in 2019 and then decreased 11.91% in 2020.
  • Tracing BMRN's Work In Process over 5 years: stood at $234.7 million in 2017, then fell by 1.54% to $231.1 million in 2018, then skyrocketed by 51.46% to $350.0 million in 2019, then dropped by 11.91% to $308.3 million in 2020, then soared by 33.78% to $412.4 million in 2021.
  • Per Business Quant, the three most recent readings for BMRN's Work In Process are $412.4 million (Q3 2021), $374.0 million (Q2 2021), and $355.8 million (Q1 2021).